Australia’s Neurizon Therapeutics, a biotech advancing innovative treatments for neurodegenerative diseases, has reported positive top-line results from the Open-Label Extension (OLE) study of its ...

Ireland-headquartered Jazz Pharmaceuticals and Denmark’s Saniona have entered into a global license agreement for Jazz to obtain exclusive worldwide rights to develop SAN2355, a highly differentiated, ...

Clinical-stage California-based biotech Mural Oncology and XOMA Royalty Corporation , a biotechnology royalty aggregator have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly ...

The UK’s National Institute for Health and Care Excellence (NICE) has today (August 21) recommended the use of Japanese pharma major Astellas’ enfortumab vedotin with MSD’s Keytruda (pembrolizumab) ...

VantAI, a specialist in generative AI for proximity drug discovery, and Halda Therapeutics, a company focused on regulated ...

Japanese ophthalmology major Santen Pharmaceutical has licensed the Asia rights to Chinese biopharma RemeGen’s ...

Swiss pharma company Idorsia announced that its novel dual endothelin receptor antagonist (ERA), Tryvio (aprocitentan), has ...

Elix has announced that fellow Japanese firm Kyorin Pharmaceutical has adopted Elix Discovery, its proprietary AI-powered ...

PTC Therapeutics yesterday revealed that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL ...

AlzeCure Pharma, a Swedish pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, has appointed Cecilia Wadell as ...

Today’s announcement (August 20) on draft guidelines from the UK’s National Institute for Health and Care Excellence (NICE) ...

The Alzheimer’s disease (AD) market across the eight major markets (8MM: USA, France, Germany, Italy, Spain, UK, Japan, and ...